The role of Bromelain and Liposomal Vitamin C in the treatment of chronic venous disease.

IF 2.4 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE
Giacomo Buso, Paolo Santini, Francesca Ghirardini, Francesca Cannavacciuolo, Adriana Visonà, Beniamino Zalunardo, Roberto Pola, Romeo Martini
{"title":"The role of Bromelain and Liposomal Vitamin C in the treatment of chronic venous disease.","authors":"Giacomo Buso, Paolo Santini, Francesca Ghirardini, Francesca Cannavacciuolo, Adriana Visonà, Beniamino Zalunardo, Roberto Pola, Romeo Martini","doi":"10.1024/0301-1526/a001184","DOIUrl":null,"url":null,"abstract":"<p><p><b></b> Chronic venous disease (CVD) is a prevalent condition leading to significant morbidity and affecting quality of life. Among conservative treatment strategies, venoactive drugs are often recommended by major guidelines for the management of CVD. Bromelain and vitamin C are now emerging as promising options in the management of several chronic diseases owing to their anti-inflammatory, immunoregulatory, and antioxidant properties, though evidence remains scarce in this setting. This systematic review of the literature, endorsed by the Italian Society of Angiology and Vascular Medicine (<i>Societa Italiana di Angiologia e Patologia Vascolare</i>, SIAPAV), aims to evaluate the efficacy and safety of these compounds in the treatment of CVD. A comprehensive search yielded nine studies, two on bromelain and seven on vitamin C. No studies have evaluated the effects of bromelain and vitamin C alone or in combination, whereas both molecules were administered in combination with other nutritional supplements. Overall, CVD-related symptoms and edema seem to improve with dietary supplement containing these two compounds, with no major safety issues reported. Bromelain and vitamin C may thus represent attractive options in the management of patients with symptomatic CVD and/or presence of venous edema, provided optimal conservative treatment is in place. Dedicated clinical studies are needed to clarify the efficacy and safety of a combination of these molecules in CVD management.</p>","PeriodicalId":23528,"journal":{"name":"Vasa-european Journal of Vascular Medicine","volume":" ","pages":"164-176"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vasa-european Journal of Vascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1024/0301-1526/a001184","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic venous disease (CVD) is a prevalent condition leading to significant morbidity and affecting quality of life. Among conservative treatment strategies, venoactive drugs are often recommended by major guidelines for the management of CVD. Bromelain and vitamin C are now emerging as promising options in the management of several chronic diseases owing to their anti-inflammatory, immunoregulatory, and antioxidant properties, though evidence remains scarce in this setting. This systematic review of the literature, endorsed by the Italian Society of Angiology and Vascular Medicine (Societa Italiana di Angiologia e Patologia Vascolare, SIAPAV), aims to evaluate the efficacy and safety of these compounds in the treatment of CVD. A comprehensive search yielded nine studies, two on bromelain and seven on vitamin C. No studies have evaluated the effects of bromelain and vitamin C alone or in combination, whereas both molecules were administered in combination with other nutritional supplements. Overall, CVD-related symptoms and edema seem to improve with dietary supplement containing these two compounds, with no major safety issues reported. Bromelain and vitamin C may thus represent attractive options in the management of patients with symptomatic CVD and/or presence of venous edema, provided optimal conservative treatment is in place. Dedicated clinical studies are needed to clarify the efficacy and safety of a combination of these molecules in CVD management.

菠萝蛋白酶和维生素C脂质体在慢性静脉疾病治疗中的作用。
慢性静脉疾病(CVD)是一种常见的疾病,导致显著的发病率和影响生活质量。在保守治疗策略中,静脉活性药物通常被推荐用于心血管疾病的治疗。菠萝蛋白酶和维生素C由于其抗炎、免疫调节和抗氧化的特性,目前正在成为治疗几种慢性疾病的有希望的选择,尽管在这方面的证据仍然很少。这项由意大利血管学和血管医学学会(Societa Italiana di Angiologia e Patologia Vascolare, SIAPAV)批准的文献系统综述旨在评估这些化合物治疗CVD的有效性和安全性。一项全面的搜索产生了九项研究,其中两项是关于菠萝蛋白酶的,七项是关于维生素C的。没有研究评估单独或联合使用菠萝蛋白酶和维生素C的效果,而这两种分子都与其他营养补充剂联合使用。总的来说,含有这两种化合物的膳食补充剂似乎改善了cvd相关症状和水肿,没有重大的安全性问题报道。因此,菠萝蛋白酶和维生素C在有症状的CVD和/或存在静脉水肿的患者的治疗中可能是有吸引力的选择,提供最佳的保守治疗。需要专门的临床研究来阐明这些分子联合治疗心血管疾病的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.90
自引率
11.10%
发文量
61
审稿时长
1 months
期刊介绍: Vasa is the European journal of vascular medicine. It is the official organ of the German, Swiss, and Slovenian Societies of Angiology. The journal publishes original research articles, case reports and reviews on vascular biology, epidemiology, prevention, diagnosis, medical treatment and interventions for diseases of the arterial circulation, in the field of phlebology and lymphology including the microcirculation, except the cardiac circulation. Vasa combines basic science with clinical medicine making it relevant to all physicians interested in the whole vascular field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信